Effector raises $45M in tranched series A

Effector Therapeutics Inc. (San Diego, Calif.) raised $45 million in a tranched series A round co-led by U.S. Venture Partners; Abingworth; Novartis Venture Funds; and SR One. Astellas Venture Management; Osage University Partners; and Mission Bay Capital also participated. Effector, which declined to disclose details of the tranches, plans to develop small molecules to selectively regulate translation of oncogenes for cancer indications. ...